Ojjaara received a reimburse recommendation from Canada’s Drug Agency, a decisive achievement in advancing access to rare blood cancer treatments. MISSISSAUGA, ON – Ojjaara (momelotinib) has received a reimburse with conditions recommendation from Canada’s… Read More
Agreement on Formulation and Finish of a Virus-Like Particle Vaccine for Phase 1 and 2 Clinical Trials MONTREAL, QC & QUEBEC CITY, QC – Aramis Biotechnologies Inc. (“Aramis”), Quebec City-based… Read More
Fabhalta® is the first oral monotherapy for previously treated and treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH)1,2 Significant unmet need remains in PNH, a chronic, rare and potentially life-threatening blood… Read More
The CASTL team is excited to announce the launch of four specialized workshops focused on Good Manufacturing Practices (GMP) in biopharmaceutical manufacturing. These workshops have been developed in direct response… Read More
Discovery of ‘ovoid cells’ reshapes our understanding of how memory works, and could open the door to new treatments for Alzheimer’s disease, epilepsy and more. Take a look around your… Read More
